Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. More precise phenotyping of cluster headache using prospective attack reports

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Acute endovascular reperfusion treatment in patients with ischaemic stroke and large-vessel occlusion (Denmark 2011–2017)

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Disturbed sleep in cluster headache is not the result of transient processes associated with the cluster period

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Autoimmun autonom ganglionopati hos en patient med nydiagnosticeret type 1-diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: Subcutaneous immunoglobulin (SCIG) is effective as maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). We investigated whether multiple subcutaneous infusions are as effective as conventional therapy with intravenous loading doses in treatment-naive patients with CIDP.

METHODS: Twenty patients fulfilling the clinical and electrophysiological criteria for CIDP were included and treated with either SCIG (0.4 g/kg/week) for 5 weeks or intravenous immunoglobulin (IVIG) (0.4 g/kg/day) for 5 days. After 10 weeks, patients were switched to the opposite treatment arm and followed for a further 10 weeks. All participants were evaluated at weeks 0, 2, 5 and 10 during both therapies. Primary outcome was combined isokinetic muscle strength (cIKS). Secondary outcomes were disability, clinical evaluation of muscle strength and the performance of various function tests.

RESULTS: All participants received both therapies, 14 completing the protocol. Overall, cIKS increased by 7.4 ± 14.5% (P = 0.0003) during SCIG and by 6.9 ± 16.8% (P = 0.002) during IVIG, the effect being similar (P = 0.80). Improvement of cIKS peaked 2 weeks after IVIG and 5 weeks after SCIG. Disability improved during SCIG treatment only. Muscle strength determined by manual muscle testing improved after 5 and 10 weeks during SCIG but only after 5 weeks during IVIG. The remaining parameters improved equally during both treatments. Plasma immunoglobulin G levels at baseline and improvement of cIKS were related.

CONCLUSION: In treatment-naive patients with CIDP, short-lasting SCIG and IVIG therapy improve motor performance to a similar degree, but with earlier maximal improvement following IVIG than SCIG treatment.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume24
Issue number2
Pages (from-to)412-418
Number of pages7
ISSN1351-5101
DOIs
Publication statusPublished - Feb 2017

    Research areas

  • Adult, Aged, Cross-Over Studies, Disability Evaluation, Female, Humans, Immunoglobulin G, Immunoglobulins, Immunoglobulins, Intravenous, Infusions, Subcutaneous, Male, Middle Aged, Muscle Strength, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Single-Blind Method, Treatment Outcome, Journal Article, Randomized Controlled Trial

ID: 52415402